KUALA LUMPUR, July 29 (Bernama) -- Bursa Malaysia rebounded to close higher on Wednesday on selective buying of defensive stocks after a volatile trading session. IPPFA Sdn Bhd director of investment strategy and country economist Mohd Sedek Jantan said consumer products and services stocks lifted the key index higher, overcoming lingering geopolitical concerns. At 5 pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) rose 3.08 points to 1,715.56 from yesterday’s close of 1,712.48. The benchmark index, which opened 1.91 points higher at 1,714.39, moved between 1,710.79 and 1,720.59 during the day’s trading. In the broader market, gainers outstripped decliners 550 to 476, while 612 counters were unchanged, 1,129 untraded, and 48 suspended. Turnover rose to 2.96 billion units valued at RM2.48 billion from 2.94 billion units valued at RM2.56 billion on Tuesday.
Hong Kong’s equity market is roaring back to life in 2025, attracting a record wave of listing applications and reclaiming its position as a dominant capital-raising centre in Asia. With 208 primary and secondary listing applications filed in just the first half of the year—surpassing the previous record of 189 in 2021—investor interest is clearly surging.
What's Driving the Boom?
A confluence of factors has positioned Hong Kong as a magnet for equity fundraising:
Currency Stability: Chinese companies are increasingly drawn to Hong Kong’s access to US dollar-pegged capital, bypassing strict capital controls on the mainland.
Foreign Inflows: Massive reallocation from international and Asian investors into Hong Kong-listed equities is fueling bullish sentiment.
Regulatory Openness: Unlike mainland China or the US, Hong Kong offers more transparent and flexible listing pathways—especially for sectors like biotech, tech, and overseas-facing businesses.
Hong Kong vs Global Peers
With US$13.9 billion raised via IPOs and secondary listings, Hong Kong has outpaced both the Nasdaq (US$9.2B) and NYSE (US$7.8B), according to KPMG. In stark contrast, London raised just £160 million in the same period—its weakest half since 1995.
This renewed strength comes as Hong Kong equities outperform Chinese A-shares in the first half, thanks to strong inflows via Stock Connect and a valuation rebound.
A-to-H Listings: Offshore Expansion in Focus
A significant portion of the IPO pipeline comes from Chinese mainland-listed firms seeking dual listings, or A-to-H structures. This trend reflects:
A desire to raise international capital
A hedge against US-China decoupling risks
The use of Hong Kong-listed stock for M&A, employee compensation, and international branding
Notable recent and upcoming listings include:
CATL (US$5.3B listing) – the world’s largest EV battery maker
Jiangsu Hengrui – pharmaceutical major
Midea – household appliance giant
Lens Technology – Apple supplier
Zijin Mining International, Chery Automobile, and possibly Shein
Will the IPO Boom Go Beyond China?
While Chinese firms dominate the pipeline, there's growing participation from international issuers. Thai beverage group IFBH’s US$100M raise in June signals a broader interest in Hong Kong as Asia’s listing venue of choice.
HKEX’s strategy of attracting Asia-focused growth companies—from specialist tech to regional consumer brands—appears to be gaining traction.
Outlook: Opportunity with Caveats
The surge in Hong Kong listings signals a strong revival in capital markets confidence, driven by cross-border interest, regulatory flexibility, and macro trends like dollar hedging and global expansion.
However, investors should watch for:
Volatility tied to US-China tensions
The actual conversion rate of applications into completed listings
Sector concentration risks, especially if sentiment shifts in tech or EV-related segments
Bottom Line:
Hong Kong’s IPO rebound is more than a short-term bounce—it reflects a structural pivot in global capital flows.For investors, this presents new opportunities to gain early exposure to high-growth Asian companies—but selectivity and a keen eye on policy developments will be key.
Comments
Post a Comment